Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation

Addiction

Volumn 106, Issue 10, 2011, Pages 1819-1826

  Taylor, Matthew ^a   Leonardi Bee, Jo ^b   Agboola, Shade ^b   McNeill, Ann ^b   Coleman, Tim ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Bupropion; Cost effectiveness; Nicotine replacement therapy; Relapse prevention; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; NICOTINE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; VARENICLINE;

ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; HUMAN; RECURRENT DISEASE; SMOKING; SMOKING CESSATION; STATISTICS; TREATMENT OUTCOME; UNITED KINGDOM;

BENZAZEPINES; BUPROPION; COST-BENEFIT ANALYSIS; DOPAMINE UPTAKE INHIBITORS; ENGLAND; EPIDEMIOLOGIC METHODS; HEALTH CARE COSTS; HUMANS; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; RECURRENCE; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; WALES;

EID: 80052758884     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03493.x     Document Type: Article

References (35)

1. Tobacco Advisory Group of the Royal College of Physicians. Nicotine Addiction in Britain. London: Royal College of Physicians of London; 2000.
2. McNeill A., Raw M., Whybrow J., Bailey P. A national strategy for smoking cessation treatment in England. Addiction 2005; 100: 1-11.
3. Godfrey C., Parrott S., Coleman T., Pound E. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction 2005; 100: 70-83.
4. Government H. M. A Smoke Free Future. A Comprehensive Tobacco Control Strategy for England. London: Department of Health; 2010.
5. Ferguson J., Bauld L., Chesterman J., Judge K. The English smoking treatment services: one-year outcomes. Addiction 2005; 100: 59-69.
6. Agboola S., McNeill A., Coleman T., Leonardi-Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105: 1362-80.
7. Office for National Statistics (ONS). Interim Revised Population Estimates: England and Wales 2000. Newport, UK: ONS; 2006.
8. Coleman T., Agboola S., Leonardi-Bee J., Taylor M., McEwen A., McNeill A. Relapse prevention in UK stop smoking services: current practice, systematic reviews of effectiveness and cost effectiveness analysis. Health Technol Assess 2010; 14: 47-64.
9. British Medical Association (BMA) and Royal Pharmaceutical Society (RPS) of Great Britain. British National Formulary. No. 56, September 2008. London: BMA and RPS; 2008.
10. Parrott S., Godfrey C., Raw M., West R., McNeil A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 1998; 53: 1-38.
11. Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking-40 years observations on male British doctors. BMJ 1994; 309: 901-11.
12. ® at).
13. Department of Health. Health Survey for England 2004. London: Department of Health; 2006.
14. Forman D., Stockton D., Moller H., Quinn M., Babbo P., De Angelis R. etal. Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol 2003; 14: 648-54.
15. Allender S., Peto V., Scarborough P., Boxer A., Rayner M. Coronary Heart Disease Statistics, 2006 edn. London: British Heart Foundation; 2006.
16. Britton M. The burden of COPD in the UK: results from the confronting COPD survey. Respir Med 2003; 197: S71-S79.
17. Peto R., Darby S., Deo H., Silcocks P., Whitley E., Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321: 323-9.
18. Department of Health and Human Services (DHSS), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Office on Smoking Health (OSH). The Health Consequences of Smoking: a Report by The Surgeon General. Washington, DC: DHSS, NCCDPHP & OSH; 2004.
19. Tengs T., Wallace A. One thousand health-related quality of life estimates. Med Care 2000; 38: 583-637.
20. Rutten-van Molken M., Oostenbrink J., Tashkin D., Burkhart D., Monz B. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130: 1117-28.
21. Tillmann M., Silcock J. A comparison of smokers' and ex-smokers' health-related quality of life. J Public Health Med 1997; 19: 268-73.
22. Sanderson H., Spiro S. Cancer of the lung, first series. In: Stevens A., Raftery J., Mant J., Simpson S., editors. Health Care Needs Assessment. Oxford: Radcliffe Publishing; 1998, p. 236-47.
23. ® at).
24. ® at).
25. ® at).
26. ® at).
27. Department of Health. NHS Reference Costs 2005. London: Department of Health; 2005.
28. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59: 1-232.
29. HM Treasury. Trend Growth: Recent Developments and Prospects. London: HM Treasury; 2002.
30. ® at).
31. Killen J. D., Fortmann S. P., Newman B., Varady A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol 1990; 58: 85-92.
32. Fortmann S. P., Killen J. D., Fortmann S. P., Killen J. D. Nicotine gum and self-help behavioral treatment for smoking relapse prevention: results from a trial using population-based recruitment. J Consult Clin Psychol 1995; 63: 460-8.
33. Song F., Raftery J., Aveyard P., Hyde C., Barton P., Woolacott N. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making 2002; 22: 26-37.
34. Yudkin P., Hey K., Roberts S., Welch S., Murphy M., Walton R. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. BMJ 2003; 327: 28-9.
35. Bourn J. Reducing Brain Damage: Faster Access to Better Stroke Care. London: National Audit Office; 2005.